article · Biomedicine & Pharmacotherapy
Investigating therapies for Alzheimer's disease, laboratory testing examined the therapeutic effects of mesenchymal stem cell-derived exosomes in an animal model of the condition. Rats treated to model Alzheimer's received these exosomes, alongside comparisons involving autophagy modulators. Administration of the exosomes improved memory performance and diminished both amyloid-beta plaque accumulation and tau phosphorylation in brain tissues. The treatment additionally promoted the growth of new neural cells, enhanced synaptic function, and curbed astrogliosis. These improvements were linked to alterations in the PI3K/Akt/mTOR signalling pathway, the modulation of autophagy, and the reduction of neuroinflammation. The intervention also influenced specific regulatory microRNAs, namely miRNA-21, miRNA-155, miRNA-17-5p, and miRNA-126-3p, demonstrating that stem cell-derived exosomes act across multiple biological mechanisms to counteract neurodegenerative pathology in vivo.
Alzheimer's disease causes progressive cognitive decline, memory loss, and brain tissue deterioration, with few options available to reverse underlying cellular damage. Demonstrating that stem cell-derived exosomes can diminish hallmark brain plaques, reduce inflammation, and stimulate neural repair in an animal model points towards multi-target biologic strategies for combating neurodegenerative conditions.
This research could inform the development of cell-free regenerative therapies targeting neurodegenerative diseases such as Alzheimer's. The primary users would be biotechnology developers and pharmaceutical companies investigating biological drug delivery and extracellular vesicles. As the evidence is drawn entirely from an in vivo rat study, the approach is at an early preclinical stage and remains distant from clinical use.
AI-generated from the published abstract. Always read the original work before citing.
Alzheimer's disease (AD) is a devastating neurological condition characterized by cognitive decline, motor coordination impairment, and amyloid plaque accumulation. The underlying molecular mechanisms involve oxidative stress, inflammation, and neuronal degeneration. This study aimed to investigate the therapeutic effects of mesenchymal stem cell-derived exosomes (MSC-exos) on AD and explore the molecular pathways involved, including the PI3K/Akt/mTOR axis, autophagy, and neuroinflammation. To assess the potential of MSC-exos for the treatment of AD, rats were treated with AlCl<sub>3</sub> (17 mg/kg/once/day) for 8 weeks, followed by the administration of an autophagy activator (rapamycin), or MSC-exos with or without an autophagy inhibitor (3-methyladenin; 3-MA+ chloroquine) for 4 weeks. Memory impairment was tested, and brain tissues were collected for gene expression analyses, western blotting, histological studies, immunohistochemistry, and transmission electron microscopy. Remarkably, the administration of MSC-exos improved memory performance in AD rats and reduced the accumulation of amyloid-beta (Aβ) plaques and tau phosphorylation. Furthermore, MSC-exos promoted neurogenesis, enhanced synaptic function, and mitigated astrogliosis in AD brain tissues. These beneficial effects were associated with the modulation of autophagy and the PI3K/Akt/mTOR signalling pathway, as well as the inhibition of neuroinflammation. Additionally, MSC-exos were found to regulate specific microRNAs, including miRNA-21, miRNA-155, miRNA-17-5p, and miRNA-126-3p, further supporting their therapeutic potential. Histopathological and bioinformatic analyses confirmed these findings. This study provides compelling evidence that MSC-exos hold promise as a potential therapeutic approach for AD. By modulating the PI3K/Akt/mTOR axis, autophagy, and neuroinflammation, MSC-exos have the potential to improve memory, reduce Aβ accumulation, enhance neurogenesis, and mitigate astrogliosis. These findings shed light on the therapeutic potential of MSC-exos and highlight their role in combating AD.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.biopha.2024.116836
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
